Related Experiment Videos
Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach
Journal of Comparative Effectiveness Research
|October 30, 2012
Summary
Regional stakeholders prioritized cancer diagnostic research, focusing on PET and MRI. Engaging stakeholders throughout the comparative effectiveness research (CER) process enhances project success and implementation.
Area of Science:
- Oncology
- Health Services Research
- Medical Imaging
Background:
- Comparative Effectiveness Research (CER) is crucial for optimizing diagnostic technologies in cancer care.
- Engaging regional stakeholders is vital for aligning research priorities with community needs.
- The western Washington State region sought to prioritize CER in cancer diagnostics.
Purpose of the Study:
- To describe a process for engaging regional stakeholders in prioritizing CER for cancer diagnostics.
- To present a novel methodology for integrating stakeholder input into CER study objectives.
- To inform the design of selected CER studies through stakeholder collaboration.
Main Methods:
- Assembled a regional stakeholder group (payers, clinicians, healthcare representatives).
- Conducted a landscape analysis (literature, expert consultation, stakeholder discussions) to identify CER topics.
- Utilized a modified Delphi/group-nominal method with a standardized framework for topic prioritization.
- Performed an 'internal analysis' of payer claims data to refine study objectives.
Main Results:
- Stakeholders identified PET and MRI in breast, lung, lymphoma, and colorectal cancers as top priorities.
- An internal analysis revealed increasing utilization and variability in advanced breast cancer imaging (2002-2009).
- The top breast cancer study objective was to assess if MRI affects treatment decisions.
Conclusions:
- Continuous stakeholder engagement significantly boosted project enthusiasm.
- Regional stakeholder involvement is key to successful CER implementation.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...